Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern linked to the increasing prevalence of metabolic syndrome, including obesity and type 2 diabetes (T2D). MASLD remains a significant clinical challenge due to the absence of effective therapeu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cell & Bioscience |
| Online Access: | https://doi.org/10.1186/s13578-025-01406-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124363469160448 |
|---|---|
| author | Zhaoxi Zhang Alice Pik-Shan Kong Vincent Wai-Sun Wong Hannah Xiaoyan Hui |
| author_facet | Zhaoxi Zhang Alice Pik-Shan Kong Vincent Wai-Sun Wong Hannah Xiaoyan Hui |
| author_sort | Zhaoxi Zhang |
| collection | DOAJ |
| description | Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern linked to the increasing prevalence of metabolic syndrome, including obesity and type 2 diabetes (T2D). MASLD remains a significant clinical challenge due to the absence of effective therapeutic interventions. Intermittent fasting (IF) has emerged as a promising non-pharmacological strategy for managing MASLD. Although the exact mechanisms underpinning the possible beneficial effects of IF on MASLD are not yet fully elucidated, the gut microbiota and its metabolic byproducts are increasingly recognized as potential mediators of these effects. The gut-liver axis may act as an important conduit through which IF exerts its beneficial influence on hepatic function. This review comprehensively examines the impact of various IF protocols on gut microbiota composition, investigating the resultant alterations in microbial diversity and metabolomic profiles, and their potential implications for liver health and the improvement of MASLD. |
| format | Article |
| id | doaj-art-cb06a21d8eaa430689b9cf60a3f7e8f6 |
| institution | OA Journals |
| issn | 2045-3701 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell & Bioscience |
| spelling | doaj-art-cb06a21d8eaa430689b9cf60a3f7e8f62025-08-20T02:34:19ZengBMCCell & Bioscience2045-37012025-05-0115112710.1186/s13578-025-01406-wIntermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axisZhaoxi Zhang0Alice Pik-Shan Kong1Vincent Wai-Sun Wong2Hannah Xiaoyan Hui3School of Biomedical Sciences, The Chinese University of Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong KongInstitute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, Shenzhen Research Institute, The Chinese University of Hong KongSchool of Biomedical Sciences, The Chinese University of Hong KongAbstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern linked to the increasing prevalence of metabolic syndrome, including obesity and type 2 diabetes (T2D). MASLD remains a significant clinical challenge due to the absence of effective therapeutic interventions. Intermittent fasting (IF) has emerged as a promising non-pharmacological strategy for managing MASLD. Although the exact mechanisms underpinning the possible beneficial effects of IF on MASLD are not yet fully elucidated, the gut microbiota and its metabolic byproducts are increasingly recognized as potential mediators of these effects. The gut-liver axis may act as an important conduit through which IF exerts its beneficial influence on hepatic function. This review comprehensively examines the impact of various IF protocols on gut microbiota composition, investigating the resultant alterations in microbial diversity and metabolomic profiles, and their potential implications for liver health and the improvement of MASLD.https://doi.org/10.1186/s13578-025-01406-w |
| spellingShingle | Zhaoxi Zhang Alice Pik-Shan Kong Vincent Wai-Sun Wong Hannah Xiaoyan Hui Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis Cell & Bioscience |
| title | Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis |
| title_full | Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis |
| title_fullStr | Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis |
| title_full_unstemmed | Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis |
| title_short | Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis |
| title_sort | intermittent fasting and metabolic dysfunction associated steatotic liver disease the potential role of the gut liver axis |
| url | https://doi.org/10.1186/s13578-025-01406-w |
| work_keys_str_mv | AT zhaoxizhang intermittentfastingandmetabolicdysfunctionassociatedsteatoticliverdiseasethepotentialroleofthegutliveraxis AT alicepikshankong intermittentfastingandmetabolicdysfunctionassociatedsteatoticliverdiseasethepotentialroleofthegutliveraxis AT vincentwaisunwong intermittentfastingandmetabolicdysfunctionassociatedsteatoticliverdiseasethepotentialroleofthegutliveraxis AT hannahxiaoyanhui intermittentfastingandmetabolicdysfunctionassociatedsteatoticliverdiseasethepotentialroleofthegutliveraxis |